



MINUTES

Utah Department of Health
Pharmacy and Therapeutics Committee

Thursday, March 16, 2017
7:15 a.m. to 8:45 a.m.
Cannon Health Building
Room 128

Committee Members Present:

Bryan Larson, PharmD
Clinton Sheffield, MD, Committee Chair
Clayton Grace, RPh
Keith Tolman, MD

Susan Siegfried, MD
Abril Atherton, PharmD

Committee Members Excused:

Jake Jones, MD
Jameson Rice, PharmD

Elizabeth Young, PharmD

Dept. of Health/Div. of Health Care Financing Staff Present:

Alyssa Pitts, RN
Merelynn Berrett, RN
Andrea Rico, CPhT

Heather Santacruz, RN

University of Utah Drug Regimen Review Center Staff Present:

Valerie Gonzales, PharmD

Other Individuals Present:

Terra Stone, Viiv Healthcare
Michelle Bice, Gilead
Cody Ball, Select Health
Elena Martinez, U of U
Jared Hafen, Utah Aids Foundation

Michele Puyear, Gilead Sciences
Stephen Glu, BMS
Douglas L. Smith, Intermountain
Joanne LaFluer, U of U
Tony Patterson, State of Utah

Meeting conducted by: Clinton Sheffield, MD

-
1. **Welcome & Housekeeping:** Clinton Sheffield opened the meeting and reminded everyone to sign in.
 2. **Review and Approval of January Minutes:** Keith Tolman made a motion to approve the minutes from January. Clinton Sheffield seconded the motion. All in favor.
 3. **Annual Training:** Tony Patterson provided annual training on Utah Code -- Title 52 -- Chapter 04 -- Open and Public Meetings Act.
 4. **HIV:** Valerie Gonzales presented a review of HIV Integrase Inhibitors, Non-Nucleoside

Reverse Transcriptase Inhibitors and Entry Inhibitors. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.

5. Public Comment:

- a. Bryan Larson read a letter from the Utah Aids Foundation requesting that Utah State Medicaid not to restrict access to antiretroviral medications by placing them on the non-preferred drug list.
- b. Dr. Doug Smith read his own letter encouraging Utah State Medicaid to keep an open formulary for antiretroviral medications. Bryan Larson clarified Utah State Medicaid does not have a formulary, rather a Preferred Drug List and a Non-Preferred drug list of which medications would require a prior authorization. Keith Tolman noted that if a medication is on the preferred drug list it saves the State of Utah a lot of money. Bryan noted that if there are supplemental rebates and a class of drugs is *not* on the preferred drug list, we are unable to claim rebates. Doug Smith encouraged keeping the DHHS recommended regimens on the Utah State Medicaid Preferred Drug List.
- c. Keith Tolman read a letter on behalf of Dr. Harry Rosado recommending Integrase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors and Entry Inhibitors to be included on the Utah State Medicaid Preferred Drug List.
- d. Terra Stone read a letter advocating for the continuation of coverage and open access for all HIV medications for recipients Utah State Medicaid living with HIV/AIDS. Keith Tolman asked if *Dolutegravir* should be a preferred HIV medication. Terra responded suggesting that all HIV medications should be accessible.
- e. Michele Puyear noted that *Elvitegravir* is currently off the market as a single product, but will be available April 2017 as a combination product.

6. **Other State Report:** Bryan Larson reported PDL listings for agents in this class in other States' Medicaid programs.

7. Committee Discussion:

- a. Keith Tolman made a motion that the following agents be preferred on the Preferred Drug List as preferred agents (based on recommendations by Dr. Harry Rosado): Dolutegravir, Raltegravir, Elvitegravir, Rilpivirine, Etravirine, Efavirenz, Nevirapine, and Maraviroc; and as non-preferred agents, Delavirdine and Enfuvirtide. Clinton Sheffield seconded the motion. All in favor, unanimous. Motion passed.
- b. Doug Smith expressed his support for Dr. Harry Rosado's recommendation.
- c. Susan Siegfried made a motion to amend the previous motion by adding a grandfathering clause with a look back of 90 days. Keith Tolman seconded the motion. All in favor, unanimous. Motion passed.

8. **Meeting Adjourned:** Clinton Sheffield motioned to close the meeting. Keith Tolman seconded. Unanimous approval.

9. **Next meeting:** Thursday, April 20, 2017 *HIV, Nucleoside/Nucleotide Reverse Transcriptase Inhibitors and Combination Products.*

Audio recording of all P&T meetings are available online at:
<https://medicaid.utah.gov/pharmacy/pt-committee?p=Committee%20Meeting%20Audio%20Recordings>